Author:
Arisue Nobuko,Palacpac Nirianne Marie Q.,Ntege Edward H.,Yeka Adoke,Balikagala Betty,Kanoi Bernard N.,Bougouma Edith Christiane,Tiono Alfred B.,Nebie Issa,Diarra Amidou,Houard Sophie,D’Alessio Flavia,Leroy Odile,Sirima Sodiomon B.,Egwang Thomas G.,Horii Toshihiro
Abstract
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in Uganda and Burkina Faso have demonstrated promising safety and immunogenicity profiles. However, the genetic diversity of sera5 in Africa and the role of allele/variant-specific immunity remain a major concern. Here, sequence analyses were done on 226 strains collected from the two clinical trial/follow-up studies and 88 strains from two cross-sectional studies in Africa. Compared to other highly polymorphic vaccine candidate antigens, polymorphisms in sera5 were largely confined to the repeat regions of the gene. Results also confirmed a SERA5 consensus sequence with African-specific polymorphisms. Mismatches with the vaccine-type SE36 (BK-SE36) in the octamer repeat, serine repeat, and flanking regions, and single-nucleotide polymorphisms in non-repeat regions could compromise vaccine response and efficacy. However, the haplotype diversity of SERA5 was similar between vaccinated and control participants. There was no marked bias or difference in the patterns of distribution of the SE36 haplotype and no statistically significant genetic differentiation among parasites infecting BK-SE36 vaccinees and controls. Results indicate that BK-SE36 does not elicit an allele-specific immune response.
Funder
Global Health Innovative Technology Fund
Ministry of Education, Culture, Sports, Science and Technology
Japan Agency for Medical Research and Development
Irish Aid
Subject
Infectious Diseases,Microbiology (medical),Immunology,Microbiology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献